AGIO
Agios Pharmaceuticals, Inc. NASDAQ Listed Jul 24, 2013$27.53
Mkt Cap $1.6B
52w Low $22.24
22.3% of range
52w High $46.00
50d MA $29.56
200d MA $33.02
P/E (TTM)
-4.0x
EV/EBITDA
-3.3x
P/B
1.4x
Debt/Equity
0.1x
ROE
-38.1%
P/FCF
-4.2x
RSI (14)
—
ATR (14)
—
Beta
0.79
50d MA
$29.56
200d MA
$33.02
Avg Volume
1.1M
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
88 Sidney Street · Cambridge, MA 02139-4169 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | -1.81 | -1.69 | +6.6% | 28.05 | +0.1% | -0.2% | +0.6% | -2.1% | -1.3% | -0.8% | — |
| Feb 12, 2026 | TNS | -1.97 | -1.85 | +6.1% | 28.07 | +2.3% | -0.4% | -0.5% | -0.9% | +3.7% | +2.3% | — |
| Oct 30, 2025 | TNS | -1.93 | -1.78 | +7.8% | 43.18 | -0.7% | +0.1% | -7.2% | -0.3% | +1.3% | -0.5% | — |
| Jul 31, 2025 | TNS | -1.74 | -1.93 | -10.9% | 37.22 | +0.1% | -6.0% | +3.3% | +0.1% | +4.2% | -1.7% | — |
| May 1, 2025 | TNS | -1.80 | -1.55 | +13.9% | 30.94 | +1.7% | -2.7% | -0.4% | -5.5% | -0.4% | -0.6% | — |
| Feb 13, 2025 | TNS | -1.69 | -1.74 | -3.0% | 33.30 | -1.1% | -0.2% | +1.2% | +1.2% | -0.8% | +4.4% | — |
| Oct 31, 2024 | TNS | 16.69 | 4.20 | -74.8% | 44.43 | +1.1% | +1.0% | -0.1% | +4.2% | +10.5% | +6.8% | — |
| Aug 1, 2024 | TNS | -1.58 | -1.69 | -7.0% | 44.50 | -5.3% | -1.2% | -3.1% | +0.0% | -0.1% | +2.9% | — |
| May 2, 2024 | TNS | -1.64 | -1.45 | +11.6% | 34.58 | +0.9% | -0.1% | -3.8% | -1.3% | -1.0% | +1.4% | — |
| Feb 15, 2024 | TNS | -1.64 | -1.72 | -4.9% | 26.80 | -1.5% | -1.1% | +2.2% | -1.1% | +11.1% | +10.8% | — |
| Nov 2, 2023 | TNS | -1.69 | -1.64 | +3.0% | 21.00 | +1.0% | +7.1% | -0.3% | +3.7% | -3.2% | -5.1% | — |
| Aug 3, 2023 | TNS | -1.60 | -1.51 | +5.6% | 25.94 | -0.7% | -1.9% | +0.4% | +1.8% | +0.2% | +2.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Truist | Maintains | Buy → Buy | — | $28.05 | $28.07 | +0.1% | -0.2% | +0.6% | -2.1% | -1.3% | -0.8% |
| Apr 21 | BofA Securities | Maintains | Buy → Buy | — | $27.07 | $26.84 | -0.8% | -2.9% | +1.6% | -3.7% | -1.6% | -3.5% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.14 | $29.58 | -15.8% | -23.0% | -2.9% | +1.6% | -3.7% | -1.6% |
| Apr 6 | JP Morgan | Maintains | Neutral → Neutral | — | $35.20 | $35.46 | +0.7% | -1.1% | +0.9% | -3.8% | -2.5% | +0.0% |
| Apr 1 | Goldman Sachs | Maintains | Neutral → Neutral | — | $33.83 | $33.89 | +0.2% | +1.1% | +3.0% | -1.1% | +0.9% | -3.8% |
| Mar 5 | Citigroup | Maintains | Buy → Buy | — | $28.19 | $28.14 | -0.2% | -1.8% | -0.8% | +3.9% | -0.9% | -0.7% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.71 | $27.85 | +0.5% | +1.3% | -0.4% | -0.5% | -0.9% | +3.7% |
| Jan 6 | JP Morgan | Maintains | Neutral → Neutral | — | $27.45 | $27.34 | -0.4% | +0.1% | +3.9% | -1.3% | +0.9% | -0.3% |
| Dec 26 | Leerink Partners | Maintains | Outperform → Outperform | — | $29.17 | $29.06 | -0.4% | -3.9% | -3.1% | +0.6% | -0.4% | -0.1% |
| Dec 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.59 | $28.00 | +13.9% | +18.6% | -3.9% | -3.1% | +0.6% | -0.4% |
| Dec 24 | Truist | Maintains | Buy → Buy | — | $24.59 | $28.00 | +13.9% | +18.6% | -3.9% | -3.1% | +0.6% | -0.4% |
| Dec 24 | BofA Securities | Maintains | Buy → Buy | — | $24.59 | $28.00 | +13.9% | +18.6% | -3.9% | -3.1% | +0.6% | -0.4% |
| Nov 21 | JP Morgan | Maintains | Neutral → Neutral | — | $24.57 | $24.66 | +0.4% | +2.7% | +5.0% | +7.3% | +2.1% | +0.6% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.34 | $23.30 | +4.3% | +10.0% | +2.7% | +5.0% | +7.3% | +2.1% |
| Nov 20 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $22.34 | $23.30 | +4.3% | +10.0% | +2.7% | +5.0% | +7.3% | +2.1% |
| Nov 20 | BofA Securities | Maintains | Buy → Buy | — | $22.34 | $23.30 | +4.3% | +10.0% | +2.7% | +5.0% | +7.3% | +2.1% |
| Nov 20 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $22.34 | $23.30 | +4.3% | +10.0% | +2.7% | +5.0% | +7.3% | +2.1% |
| Nov 20 | Goldman Sachs | Maintains | Neutral → Neutral | — | $22.34 | $23.30 | +4.3% | +10.0% | +2.7% | +5.0% | +7.3% | +2.1% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.61 | $35.00 | -13.8% | -11.0% | -0.3% | +1.1% | -0.7% | -1.3% |
| Jul 28 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $40.00 | $39.99 | -0.0% | -7.0% | +1.4% | -0.5% | -0.9% | -6.0% |
| Jul 22 | BofA Securities | Maintains | Buy → Buy | — | $39.92 | $39.58 | -0.9% | -0.7% | +2.3% | -2.2% | +0.9% | -7.0% |
| May 2 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $30.94 | $31.47 | +1.7% | -2.7% | -0.4% | -5.5% | -0.4% | -0.6% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $35.22 | $36.14 | +2.6% | +0.7% | -0.8% | -2.1% | -0.3% | +3.5% |
| Dec 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.96 | $42.19 | +0.5% | -7.0% | -8.2% | -1.1% | -0.2% | -3.3% |
| Dec 10 | RBC Capital | Maintains | Outperform → Outperform | — | $48.64 | $48.65 | +0.0% | -5.4% | -5.8% | -12.0% | +2.1% | +9.5% |
| Dec 9 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $61.64 | $56.11 | -9.0% | -21.1% | -5.4% | -5.8% | -12.0% | +2.1% |
| Nov 1 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $44.43 | $44.93 | +1.1% | +1.0% | -0.1% | +4.2% | +10.5% | +6.8% |
| Sep 27 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $48.05 | $45.57 | -5.2% | -5.1% | -2.6% | -4.4% | -1.6% | -2.9% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $45.54 | $46.82 | +2.8% | +4.0% | -1.8% | -1.7% | +1.8% | +5.2% |
| Aug 2 | RBC Capital | Maintains | Outperform → Outperform | — | $44.50 | $42.14 | -5.3% | -1.2% | -3.1% | +0.0% | -0.1% | +2.9% |
| Jun 4 | RBC Capital | Maintains | Outperform → Outperform | — | $43.83 | $44.05 | +0.5% | +8.0% | +3.1% | -2.1% | -0.4% | -0.8% |
| Jun 4 | Goldman Sachs | Maintains | Neutral → Neutral | — | $43.83 | $44.05 | +0.5% | +8.0% | +3.1% | -2.1% | -0.4% | -0.8% |
| May 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $34.58 | $34.90 | +0.9% | -0.1% | -3.8% | -1.3% | -1.0% | +1.4% |
| Feb 23 | JP Morgan | Maintains | Neutral → Neutral | — | $29.78 | $29.87 | +0.3% | +10.8% | -0.4% | +5.9% | -3.3% | -4.0% |
| Feb 16 | RBC Capital | Maintains | Outperform → Outperform | — | $26.80 | $26.41 | -1.5% | -1.1% | +2.2% | -1.1% | +11.1% | +10.8% |
| Nov 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $21.00 | $21.20 | +1.0% | +7.1% | -0.3% | +3.7% | -3.2% | -5.1% |
| Aug 7 | JP Morgan | Maintains | Neutral → Neutral | — | $25.46 | $25.46 | +0.0% | +0.4% | +1.8% | +0.2% | +2.8% | -0.5% |
| Jun 27 | RBC Capital | Maintains | Outperform → Outperform | — | $27.47 | $27.92 | +1.6% | +2.4% | +3.8% | -6.0% | +3.2% | -0.5% |
| Feb 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.18 | $30.40 | +0.7% | +0.1% | +0.4% | +2.0% | -4.8% | -2.2% |
| Dec 1 | JP Morgan | Maintains | Neutral → Neutral | — | $30.14 | $29.93 | -0.7% | -2.5% | +7.2% | -5.5% | -4.0% | -2.3% |
| Nov 17 | Goldman Sachs | Upgrade | Sell → Neutral | — | $27.13 | $27.92 | +2.9% | +5.4% | -1.3% | +2.9% | -1.2% | +0.6% |
| Aug 5 | SVB Leerink | Maintains | Outperform → Outperform | — | $28.61 | $27.82 | -2.8% | +3.9% | -1.2% | -6.8% | +3.1% | -7.9% |
| Jul 27 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $19.51 | $20.59 | +5.5% | +10.8% | -0.5% | +0.2% | -1.3% | +7.8% |
| May 24 | Goldman Sachs | Maintains | Sell → Sell | — | $21.09 | $20.52 | -2.7% | -7.7% | +0.8% | -1.2% | +2.3% | -1.8% |
| May 17 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $22.14 | $22.98 | +3.8% | +0.9% | -5.3% | -2.6% | +2.4% | -0.0% |
| Mar 7 | Goldman Sachs | Maintains | Sell → Sell | — | $31.53 | $31.45 | -0.3% | -1.9% | -0.8% | +2.7% | -0.3% | -8.7% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.26 | $32.43 | +0.5% | -0.4% | -1.9% | -1.9% | -0.8% | +2.7% |
| Feb 25 | RBC Capital | Maintains | Outperform → Outperform | — | $29.13 | $29.11 | -0.1% | +5.7% | +1.1% | +3.4% | +0.2% | -0.4% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.55 | $27.12 | -1.6% | +5.7% | +5.7% | +1.1% | +3.4% | +0.2% |
| Feb 22 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $29.42 | $28.58 | -2.9% | -1.9% | -4.5% | +5.7% | +5.7% | +1.1% |
No insider trades available.
8-K
Agios Pharmaceuticals, Inc. -- 8-K Filing
Agios Pharmaceuticals is gaining momentum with AQVESME's thalassemia launch showing early traction and a planned sickle cell sNDA submission positioning the company for multiple clinical and commercial catalysts throughout 2026.
Apr 29
8-K
Agios Pharmaceuticals, Inc. -- 8-K Filing
Agios Pharmaceuticals' FDA-approved AQVESME achieved $54 million annual revenue while advancing mitapivat into sickle cell disease trials, supported by $1.2 billion in cash reserves.
Feb 12
Data updated apr 24, 2026 4:33pm
· Source: massive.com